Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland

Cited by (157)

Items 101–157 of 157

1. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
   Saleh Fahad Alqifari, Omar Al Komi, Abdullah Esmail, Khadijeh Alkhawami, Shahd Yousri, Mohamad Ayham Muqresh, Nawwarah Alharbi, Abdullah Abdulaziz Abdulwahab Khojah, Ahmed Mohammed Aljabri, Abdulrahman Allahham et al. · 2024 · World Journal of Diabetes
2. The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
   Gašper Tonin, Stjepan Eržen, Zala Mlinarič, Dubravka Jurišić‐Eržen, Simon Horvat, Tanja Kunej, Jasna Klen · 2025 · Obesity Reviews
3. Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment
   Maria Elena Lunati, Valeria Grancini, Carla Maria Colombo, Eva Palmieri, Veronica Resi, Michela Perrino, Emanuela Orsi, Laura Fugazzola · 2015 · Metabolism
4. Age-Related Decrease in Glucagon-Like Peptide-1 in Mouse Prefrontal Cortex but Not in Hippocampus Despite the Preservation of Its Receptor
   Ryo Ohshima · 2015 · American Journal of BioScience
5. The effect of antidiabetic drugs on bone metabolism: a concise review
   Stavroula Psachna, Maria Eleni Chondrogianni, Konstantinos D. Stathopoulos, Antonis Polymeris, Antonios Chatzigeorgiou, Efstathios Chronopoulos, Symeon Tournis, Eva N. Kassi · 2024 · Endocrine
6. Glucagon-like Peptide-1 Receptor Agonists
   Logan Collins, Ryan A. Costello · 2019 · StatPearls
7. The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
   Zhiyuan Cheng, Shuang Wang, Fu‐Rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jin-Kui Yang, Dongfeng Gu · 2024 · Journal of Diabetes
8. Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions
   Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed · 2026 · Obesity Medicine
9. ICH S1 prospective evaluation study and weight of evidence assessments: commentary from industry representatives
   John L. Vahle, Joe Dybowski, Michael J. Graziano, Shigeru Hisada, Jose Lebron, Thomas Nolte, Ronald W. Steigerwalt, Kenjiro Tsubota, Frank D. Sistare · 2024 · Frontiers in Toxicology
10. Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
    Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber, Carol Wysham · 2012 · Endocrine Practice
11. Impaired glucose metabolism treatment and carcinogenesis
    Artur Matyszewski, Anna Malgorzata Czarnecka, Maciej Kawecki, PIOTR KORZEŃ, ILAN J. SAFIR, Wojciech Kukwa, Cezary A. Szczylik · 2015 · Oncology Letters
12. Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
    Subramanian Kannan, Christian E. Nasr · 2015 · Cleveland Clinic Journal of Medicine
13. Diabetes therapy and cancer risk: Where do we stand when treating patients?
    Grace E. Ching Sun, Sangeeta Rao Kashyap, Christian E. Nasr · 2014 · Cleveland Clinic Journal of Medicine
14. Cancer biology in diabetes update: Focusing on antidiabetic drugs
    Emi Kawakita, Keizo Kanasaki · 2024 · Journal of Diabetes Investigation
15. Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study
    Zhijun Zhang, Jingyun Yang, Ling Gao · 2025 · Endocrine Practice
16. Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
    Matthias Schott, A. Thiel · 2012 · Yearbook of Endocrinology
17. Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance
    Armando Patrizio, Samantha Kass Newman, Robert Michael Tuttle, Laura Boucai · 2025 · Journal of the Endocrine Society
18. Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
    Armando Patrizio, Audrey Mauguen, James A. Fagin, Azeez Farooki, Stephanie A. Fish, James Flory, Samantha Kass Newman, Lubaina S. Presswala, Mona M. Sabra, Robert Michael Tuttle et al. · 2026 · The Journal of Clinical Endocrinology & Metabolism
19. Activation of G-Protein-Coupled Receptors and Thyroid Malignant Tumors: The Jury is Still Out
    Robert F. Gagel · 2011 · Endocrine Practice
20. Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
    Ajay Sood, Arthur Swislocki · 2019 · Metabolic Syndrome and Related Disorders
21. Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes
    Clement O Acheampong, John B. Buse, Klara Rachel Klein, Lawrence T. Kim, Joshua M. Evron, Anna R. Kahkoska, Caroline A. Thompson, Tiansheng Wang, Virginia Pate, Peter Leese et al. · 2025 · BMJ Open Diabetes Research & Care
22. Calcitonin and procalcitonin: Revisiting the overlooked role of C cells
    Eleonore Fröhlich, Richard Wahl · 2025 · Metabolism
23. Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy
    Gladys Teitelman · 2014 · Endocrinology
24. GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications
    Sedat Arslan, Ayça Aydin · 2026 · Academia oncology.
25. GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
    Xinyao Wang, Rutao Lin, QinMei Sun, Xin Xin, Qin Feng · 2026 · Pharmacological Research
26. Effect of Sitagliptin (Januvia) on the Thyroid Gland of Adult Male Albino Rats in an Experimental Model of Type II Diabetes Mellitus - (Biochemical, Histological and Immunohistochemical Studies)
    Olfat A. Abd-El Aty, Sahar Badr El-Din · 2015 · Basic Sciences of Medicine
27. Effect of Four-Week Semaglutide Therapy and Its Combination with Intranasal Insulin on Thyroid and Gonadal Status in Male Rats with Type 2 Diabetes
    Kira Viktorovna Derkach, Inna I. Zorina, Irina V. Fedorchuk, A. O. Shpakov · 2025 · Journal of Evolutionary Biochemistry and Physiology
28. Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
    Sabina Semiz · 2025 · Health Sciences Review
29. The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care
    Angela D. Mazza · 2025 · Cureus
30. Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide
    Lauren H Beshay, Jitin Makker, Susan Ahern · 2026 · Cureus
31. Short-term effect of tirzepatide on serum calcitonin in adults with obesity
    Nicholas Angelopoulos, George Simeakis, Ioannis Androulakis, Andreas A Rizoulis, Anastasios Boniakos, Paraskevi Mentzelopoulou, Areti Korakovouni, Dimitra Zianni, Valentina Petkova, Sarantis Livadas et al. · 2026 · Endocrine
32. GLP-1 Receptor Agonists in Ear, Nose and Throat: A Review of Clinical Implications, Side Effects and High-Risk Airway Surgery Considerations
    Sivagowri Somasundaram, James Nightingale, Subhapriya Sreedharan, Claire Frauenfelder · 2026 · Ear Nose & Throat Journal
33. Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology – Head and Neck Surgery: A Review
    Brady J. Anderson, Douglas J. Van Daele, Alexander D. Claussen, Zachary G. Tanenbaum, Scott R. Owen · 2026 · Annals of Otology Rhinology & Laryngology
34. Exploring the impact of social media on patient perceptions and utilization patterns of glucagon-like peptide-1 agonists: A comprehensive analysis in the digital health era
    Khalid Alfares, Raghad Ali Alosaimi, Bushra Obaidallah Alqurayqiri, Raneem W. Malibari, Raghad B Babader, Ghazal Albluwe, Sara Hesham Zaki Taha, Shahad Abdullah Alharbi, Roba Mohammed Hamdan · 2025 · Saudi Journal of Internal Medicine
35. Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY
    Sheila Anne Doggrell · 2014 · Expert Review of Endocrinology & Metabolism
36. Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
    Lis Marina de Mesquita Araújo, Sumaya Feguri, Thereza Lopes de Oliveira, Fernanda Batista Pedrosa, Rodrigo Garcez Guimarães, Larissa Bianca Paiva Cunha de Sá, Denise Rosso Tenório Wanderley Rocha, Alberto Krayyem Arbex · 2016 · Open Journal of Endocrine and Metabolic Diseases
37. DOUBLE EDGE EFFECT OF DPP4 INHIBITOR SITAGLIPTIN, A TYPE-2 ANTI-DIABETIC DRUG, ON INFLAMMATION, INJURY AND CANCER
    Biplab Giri, Mrinmoy Sarkar, Sananda Dey · 2017 · Journal of Stem Cell and Regenerative Biology
38. In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?
    Jean Claude Reubi · 2017 · Journal of Nuclear Medicine
39. Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism
    Sifan Zou, Alexandria D. McDow, Zeb Ijaz Saeed, Tieying Hou · 2023 · Cureus
40. Glucagonlike Peptide-1 Receptor Expression in the Thyroid Gland: A Case of “Hide-and-Seek”?
    Elliot Sternthal · 2011 · Endocrine Practice
41. New pharmacological approaches to diabetes management
    Abdallah Al Eyadeh, Paul E Jennings · 2015 · Practice Nursing
42. Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
    Eun-Hee Cho · 2013 · Journal of Korean Diabetes
43. Treatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
    GERALD H. TOMKIN · 2014 · Pharmaceutical Regulatory Affairs Open Access
44. Debate on diabetes drugs gathers pace
    Amy Maxmen · 2012 · Nature
45. Eksenatid Tedavisinde Tiroid İnce İğne Aspirasyon Biyopsisi ve Kalsitonin Yıkamanın Yeri Role of Thyroid Fine Needle Aspiration Biopsy and Calcitonin Wash-Out During Exenatide Therapy
    Bengür Taşkıran, Güven Barış Cansu · 2017 · OSMANGAZİ JOURNAL OF MEDICINE
46. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Disorders
    Jothydev Kesavadev, RAJIV R. KOVIL, Debasis Basu, Soumyabrata Roy Chaudhuri, Mithun Bhartia · 2022 · International Journal of Diabetes and Technology
47. Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis
    Jaber H. Jaradat, Rawan Alahmad, Maha Al Jaghbeer, Ahlam A Abdelaziz, Nour Abu Afifeh, Ghazi Abu Afifeh, Asad Rao, Amjad Alzoubi, Abdulqadir J. Nashwan · 2025 · Cureus
48. Drug Repurposing: Harnessing the Therapeutics from Antidiabetic Molecules
    Archana Bhatta, Priyanka Mahale, Harapriya Baral, D. K. Yuvaraj, Ravinder Kumar Kaundal · 2026 · Springer eBooks
49. Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?
    Florin-Dumitru Mihălțan, Corina-Ioana Borcea, Ancuţa Alina Constantin · 2026 · Life
50. THE DARK SIDE OF GLP-1 ANALOGS: ADVERSE EFFECTS, LIMITATIONS, AND SAFETY CONCERNS
    Katarzyna Dudzińska, Adam Kaftan, Jan Plenikowski, Aleksander Kahsin, Sandra Kacprzak, Aleksandra Greluk, Jonasz Żuk, Wojciech Ciszewski, Alicja Jurewicz, Zofia Plenikowska · 2026 · International Journal of Innovative Technologies in Social Science
51. Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
    Sandro La Vignera, Rosita Angela Condorelli · 2026 · Biomedicines
52. Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
    L. Rajan, Johannes Hofland, Eskeatnaf Mulugeta, Wouter W. de Herder · 2026 · European Journal of Endocrinology
53. The effect of sex and endurance exercise training on the incretin signaling pathway in 17 rat tissues
    Christopher A. Jin, Gina M. Many, Connor Scott Reynoso Spurrier, Philip Borsellino, Matthew Thomas Wheeler, Joshua Adkins, Michael P. Snyder, Christopher B. Newgard, Shlomit Radom‐Aizik, Dan M. Cooper et al. · 2026 · Physiological Genomics
54. Semaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms
    Luiza Barseghyan, Iqbal Munir, Steven Chrysafides, Alfred Simental, Salma Khan · 2026 · Journal of Clinical Medicine
55. Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score–Matched Retrospective Cohort Study Using the TriNetX Network
    Muhammad Ali Ibrahim Kazi, Junaid Khan, Syed Musa Mufarrih, Maham Siddiqui, Huzaifa Ul Haq Ansari, Muhammad Ahmed, Imran Qureshi, Abdulhameed M. Al-Sabban, Nihaal P. Karnik, Andrew J. Gilman et al. · 2026 · Journal of Gastrointestinal Cancer
56. Suitability of the ICH S1B(R1) weight-of-evidence framework to evaluate glucagon-like protein-1 receptor agonist (GLP-1RA) carcinogenicity risk
    Katherine Adair Roach, Manoochehr Khazaee, Isaac Mohar, Denali Boon, Brigitte Cronin, Alex G. Gauthier · 2026 · Regulatory Toxicology and Pharmacology
57. GLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE
    Aleksandra Milewska, Anna Bociąg, Konrad Kowalski, Rafał Marciniak, Łukasz Ptach · 2026 · International Journal of Innovative Technologies in Social Science